Risk Materials

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

Caprelsa ( Vandetanib) – Patient Card - Risk Minimisation Information for Patients

This medicine is subject to additional monitoring. This will allow quick identication of new safety information. You can help by reporting any side effects you may get. In the UK see www.mhra.gov.uk/yellowcard for how to report side effects

Caprelsa (Vandetanib) - Patient Guide - Risk Minimisation Information for Patients

The guide should be provided to patients prior to treatment by the prescribing physician and includes a description of the risks of treatment, guidance on what to do in the event of risks occurring including your doctors contact details and an overview of treatment monitoring

Caprelsa (Vandetanib) - Risk minimisation HCP Guide

For hard copies please contact our medical information department at 0845 372 7101 or email uk-medicalinformation@sanofi.com

For Healthcare Professionals

Caprelsa (Vandetanib) -Healthcare Professional Letter

For hard copies please contact our medical information department at 0845 372 7101 or email uk-medicalinformation@sanofi.com

For Healthcare Professionals

Send us feedback

If you would like to make a comment or send us feedback on this material, click here.